ImmuCell CorporationICCCNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+1.9%
5Y CAGR+4.3%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+1.9%/yr
Quarterly compound
5Y CAGR
+4.3%/yr
Consistent
Percentile
P100
Near historical high
vs 5Y Ago
1.2x
Modest growth
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 33.98% |
| Q3 2025 | 16.39% |
| Q2 2025 | -4.26% |
| Q1 2025 | 6.37% |
| Q4 2024 | 1.35% |
| Q3 2024 | -13.51% |
| Q2 2024 | 19.04% |
| Q1 2024 | 11.54% |
| Q4 2023 | -10.31% |
| Q3 2023 | 6.69% |
| Q2 2023 | -13.66% |
| Q1 2023 | -8.25% |
| Q4 2022 | 32.14% |
| Q3 2022 | 0.46% |
| Q2 2022 | -20.65% |
| Q1 2022 | 12.92% |
| Q4 2021 | 20.48% |
| Q3 2021 | 28.11% |
| Q2 2021 | -9.20% |
| Q1 2021 | -12.83% |
| Q4 2020 | 27.51% |
| Q3 2020 | -4.16% |
| Q2 2020 | -16.62% |
| Q1 2020 | -3.91% |
| Q4 2019 | 23.61% |
| Q3 2019 | -8.12% |
| Q2 2019 | -4.88% |
| Q1 2019 | -3.15% |
| Q4 2018 | 18.83% |
| Q3 2018 | -2.95% |
| Q2 2018 | -3.83% |
| Q1 2018 | 7.12% |
| Q4 2017 | 7.09% |
| Q3 2017 | 4.10% |
| Q2 2017 | -10.56% |
| Q1 2017 | 5.74% |
| Q4 2016 | -0.10% |
| Q3 2016 | 1.01% |
| Q2 2016 | 10.82% |
| Q1 2016 | -12.58% |